Author： Beaulieu D. Ohemeng K.A.
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.9, Iss.8, 1999-08, pp. : 1021-1028
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This review focuses on patents published between January 1996 and March 1999 covering bacterial tRNA synthetase inhibitors as antibacterial agents. Nine of the eleven patents issued during this period claim new formulations, forms and uses as well as new derivatives of pseudomonic acid A (mupirocin, SmithKline Beecham), a natural product inhibitor of isoleucyl-tRNA synthetase. One patent describes a new use for indolmycin, an inhibitor of tryptophanyl-tRNA synthetase, and another discloses a novel class of isoleucyl-tRNA synthetase inhibitors.
Related content
Access to resources
Recommend
Aminoacyl-tRNA Synthetase Inhibitors As Potent Antibacterials
Current Medicinal Chemistry, Vol. 19, Iss. 21, 2012-07 ,pp. :
Therapeutic possibilities in CJD: patents 1996 - 1999
By Knight R.
Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 1, 2000-01 ,pp. :